Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Chemicals Press Releases.
Press releases published on May 8, 2025
BeautyHealth Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
LONG BEACH, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2025 (“Q1 2025”). “ …
Inseego Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Q1 2025 revenue of $31.7 million Q1 2025 positive Adjusted EBITDA of $3.7 million and GAAP Net Loss of $1.6 million Ninth consecutive quarter of positive Adjusted EBITDA SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Inseego Corp. (Nasdaq: INSG) (the “Company …
Brilliant Earth Announces Participation in B. Riley Securities 25th Annual Investor Conference
GlobeNewswire
·
May 8, 2025
SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (NASDAQ: BRLT), an innovative, global leader in ethically sourced fine jewelry, today announced that the Company will participate in the B. …
Aqua Metals Expands Product Platform with Advancements in Nickel, MHP, and LFP Recycling; Reports First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
RENO, Nev., May 08, 2025 (GLOBE NEWSWIRE) -- Aqua Metals (NASDAQ: AQMS), an innovator in domestic critical minerals refining, AquaRefining™, today reported financial results for the first quarter ended March 31, 2025, and highlighted major technology and …
Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025
GlobeNewswire
·
May 8, 2025
REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its …
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials …
AVITA Medical Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025 …
PDF Solutions® Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
SANTA CLARA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of comprehensive data solutions for the semiconductor and electronics ecosystem, today announced financial results for its first quarter ended …
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of …
Metsera to Present at Bank of America 2025 Global Healthcare Conference
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit …
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
GlobeNewswire
·
May 8, 2025
1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to …
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
GlobeNewswire
·
May 8, 2025
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
GlobeNewswire
·
May 8, 2025
– Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed …
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
GlobeNewswire
·
May 8, 2025
Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in …
Colliers adds top-tier firm to Canadian engineering platform
GlobeNewswire
·
May 8, 2025
TORONTO and CALGARY, Alberta, May 08, 2025 (GLOBE NEWSWIRE) -- Colliers (NASDAQ, TSX: CIGI) announced today that its Canadian engineering platform Englobe Corporation (“Englobe”) has acquired Higher Ground Consulting Inc. (“Higher Ground”), a leading …
First Quantum Minerals Announces Voting Results for the Election of Directors
GlobeNewswire
·
May 8, 2025
TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) announced that the nominees listed in the Management Information Circular for the 2024 Annual Meeting of Shareholders (the “Annual Meeting”) …
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 8, 2025
Strong execution and progress across pipeline with multiple key data read outs expected in 2025 Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in June Phase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU …
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewswire
·
May 8, 2025
Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual …
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
GlobeNewswire
·
May 8, 2025
Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity model In vitro data reported from new preclinical study …
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 8, 2025
Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH- …